Table 1.
Non-Progressors | Progressors | Statistical Significance (P-value) | |
---|---|---|---|
Number of subjects | 226 | 48 | |
Age at baseline | 67.42 (SD 6.46) | 69.33 (SD 8.20) | 0.0788 |
Gender (male/female) | 90/136 | 18/30 | 0.7649 |
Education | 15.85 (SD 2.50) | 15.13 (SD 2.48) | 0.0703 |
CDR slope | 0 | 0.0607(SD 0.082) | 8.45*10−24 |
% Baseline CDR = 0 | 94% | 90% | 0.3388 |
MMSE Slope | 0 | −0.345 (SD 0.580) | 7.5*10−10 |
Length of time in study | 8.16 (SD 3.76) | 10.42 (SD 5.35) | 5.7*10−4 |
APOE status (e2*/e3e3/e3e4 or e4e4) | 39/126/61 | 8/22/18 | 0.4819 |
Race (Caucasian/African American/Asian) | 202/23/1 | 45/3/0 | 0.6251 |
Ethnicity (Non-Hispanic/Hispanic) | 225/1 | 48/0 | 0.6443 |
Amyloid-β+ baseline | 46 (20%) | 25 (53%) | 1.0*10−5 |
Amyloid-β+ last follow-up | 73 (32%) | 27 (56%) | 0.002 |
Number of amyloid follow-up visits | 2.65 (SD 0.98) | 2.77 (SD 0.99) | 0.4094 |
Number of MRI follow-up visits | 3.15 (SD 1.01) | 3.14 (SD 1.05) | 0.9242 |
CDR, clinical dementia rating; MMSE, mini-mental state examination. Average age, education, CDR and MMSE slopes (per year) and length of time in study are shown along with SD. For categorical comparisons, we used χ2 test, while for continuous variables, we used a one-way analysis of variance.